



Press  
release

Montpellier, December 19<sup>th</sup> 2019 – 17h45 CET

## End of BCS financing contract

Intrasense™ (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® designer, announces the end of the financing contract by BCS (Bonds Convertibles into Shares) concluded with the Luxembourg fund European High Growth Opportunities Securitization Fund (EHGO) member of the Alpha Blue Ocean group.

### Intrasense™ announces the end of the bond convertible into shares financing contract

This financing contract concluded on August 27<sup>th</sup>, 2018 with the EHGO fund took the form of a reserved issue of bonds convertible into shares. At the request of Intrasense™ and in agreement with the EHGO fund, this financing contract ends on December 18<sup>th</sup>, 2019.

Terms of the contract termination agreement provide for (i) the drawing and financing by EHGO of the 2 last tranches of 125,000 euros of nominal value each, under the conditions of the financing contract with immediate conversion into shares of issued BCS, as well (ii) the payment by Intrasense™ of an indemnity for termination of the contract of 132,500 euros.

This contract, suspended since January 28<sup>th</sup>, 2019, will have enabled Intrasense™ to finance its business development plan, to strengthen its financial structure and to meet current operational expenses.

Pierre Vannineuse, founder and CEO of Alpha Blue Ocean and sole director of EHGO, indicates: *"We are happy to have supported Intrasense during this period and to have given them financial flexibility allowing them to set up their strategic project. We strongly believe in the potential of the company and its team and we do not rule out staying with them as shareholders in the coming months."*

### A relevant and effective strategy

Nicolas Reymond, CEO of Intrasense™, comments: *"Our financial partner has given us the flexibility needed during this pivotal period, and we thank him. As part of the consolidation of our results, we believe it is key to give visibility and security to our shareholders and thus continue the implementation of our strategy."*



The strategic choices implemented by the new management over the past two years once again demonstrate their relevance, with the maintenance of operational balance, a significant increase in all financial indicators and a positive net result in the first half of 2019. The company wants to stay the course for the coming months. Cash management remains a priority and a key element, as well as investments to build growth in the coming months and years.

#### About Intrasense™

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: [www.intrasense.fr](http://www.intrasense.fr)

#### Contacts

Intrasense  
Jérémy Peyron  
Marketing & Communication manager  
1231 avenue du Mondial 98, 34000  
Montpellier, FRANCE  
Tel: +334 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor Relations and Financial  
Communication  
Roxane Gbedigro

Tel: +331 44 71 94 94  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

